DLC-1 基因在MCF-7 人乳腺癌细胞系中低表达的机制探究

目的:探究DLC-1基因在MCF-7人乳腺癌细胞系中低表达的机制。方法:应用甲基化特异性PCR(MSP)检测人乳腺癌细胞MCF-7的DLC-1基因甲基化状态,不同浓度的5-氮杂-2’-脱氧胞嘧啶(5-Aza-CdR)处理人乳腺癌细胞MCF-7,RT-PCR及Real-time PCR定量检测用药前后细胞中DLC-1基因mRNA表达水平变化。结果:DLC-1基因启动子区CpG岛呈甲基化状态,经过5-Aza-CdR处理后,DLC-1基因启动子区呈去甲基化状态,并且其mRNA恢复表达。结论:抑癌基因DLC-1 CpG岛甲基化是导致该基因低表达的原因之一,5-Aza-CdR能逆转DLC-1基因甲基化状态。     

DLC-1基因在MCF-7人乳腺癌细胞系中低表达的机制探究

目的：探究DLC-1基因在MCF-7人乳腺癌细胞系中低表达的机制。方法：应用甲基化特异性PCR（MSP）检测人乳腺癌细胞MCF-7的DLC-1基因甲基化状态,不同浓度的5-氮杂-2＇-脱氧胞嘧啶（5-Aza-CdR）处理人乳腺癌细胞MCF-7,RT-PCR及Real-time PCR定量检测用药前后细胞中DLC-1基因mRNA表达水平变化。结果：DLC-1基因启动子区CpG岛呈甲基化状态,经过5-Aza-CdR处理后,DLC-1基因启动子区呈去甲基化状态,并且其mRNA恢复表达。结论：抑癌基因DLC-1 CpG岛甲基化是导致该基因低表达的原因之一,5-Aza-CdR能逆转DLC-1基因甲基化状态。     

抑癌基因DLC-1的研究进展

DLC-1(肝癌缺失基因1)是近年来被发现的一种重要的抑癌基因,目前研究发现其在多种肿瘤的发生、发展过程中产生了重要的作用。随着基因技术及分子生物技术的飞速发展,关于DLC-1基因以及与之相关的上、下游靶基因,DLC-1基因的甲基化修饰及其相互作用的信号传导通路的研究将更深入、更彻底、更清楚。通过构建肿瘤动物实验模型,我们可以对人类各种肿瘤进行去甲基化药物治疗,分析实验结果,综合评估治疗指征,为临床上对肿瘤的治疗提供理论基础及实践指导。相信在不久的将来,针对DLC-1基因在肿瘤分子生物学研究有望成为多种肿瘤诊断、治疗的突破。     

BRCA1基因与乳腺癌

乳腺癌易感基因1(BRCA1)是具有遗传倾向的乳腺癌和卵巢癌的易感基因,且是一种抑癌基因.BRCA1基因的突变与家族性乳腺癌及它在细胞周期的调节,DNA损伤修复,基因的转录调控和诱导细胞凋亡方面起着重要作用.BRCA1基因的突变与家族性乳腺癌及卵巢癌的发生密切相关,对BRCA1分子功能的研究,将有利于阐明肿瘤发生的机理关.BRCA1的启动子甲基化与散发性乳腺癌有关.本文拟对BRCA1的结构,功能以及它的甲基化,突变,杂合性丢失对乳腺癌的影响作一综述.     

甲基转移酶对鼻咽癌细胞中DLC-1基因表达的影响

肝癌缺失基因-1(deleted in liver cancer-1,DLC-1)在多种肿瘤中呈现表达缺失或表达下调,这种异常表达主要与由DNA甲基转移酶(DNA methyltransferases,DNMTs)参与的启动子区异常甲基化有关。RT-PCR结果显示DLC-1在永生化鼻咽上皮细胞NP69和干扰DNMTs的5-8F细胞中的表达水平较未干扰的鼻咽癌细胞明显升高。甲基化特异性PCR(methylation-specific PCR,MSPCR)结果则表明DLC-1启动子区在表达下调或缺失的鼻咽癌细胞中均存在异常高甲基化,而干扰DNMTs后5-8F细胞中DLC-1启动子区甲基化状态被逆转,其中特异性干扰DNMT1后效果略为显著,提示DNA甲基转移酶活性对于鼻咽癌中DLC-1启动子区甲基化水平具有重要的调控作用,而DNMT1的调控作用更为突出。     

乳腺癌易感基因BRCA1的研究进展

BRCA1基因是目前发现的外显率最高的乳腺癌易感基因之,编码一个相对分子质量为220000的多功能核蛋白,作用于一系列维持基因组稳定性的细胞通路,包括DNA损伤修复、细胞周期检验点激活、蛋白泛素化、染色质重组,以及转录调控和凋亡等。BRCA1丢失将导致显著的遗传不稳定性和生长停滞。着重介绍近年来BRCA1基础研究方面的进展,并讨论BRCA1与乳腺癌的临床关联性。     

DLC-1与肝癌关系研究

DLC-1基因是一种肿瘤抑制基因,位于人类染色体8p21．3-22。它是RhoA特异性GTP酶的激动蛋白,与调控细胞增殖和粘附的信号传导通路关系密切,在人类多种肿瘤中呈低表达或表达缺失。研究发现DLC-1基因在原发性肝癌(HCC)及肝癌细胞系中表达缺失,提示该基因在原发性肝癌中抑制了肝癌细胞的增殖。DLC-1表达的恢复引起了caspase-3介导的细胞凋亡,抑制肝癌细胞的生长和癌细胞的浸润,从而在肝细胞癌的转移、侵袭及肿瘤细胞的生物特性方面发挥作用。因其与肝癌发生,转移乃至复发关系密切,使其在肝癌早期发现,早期预测肝癌的转移复发及肝癌的预后方面发挥重要角色。     

乳腺癌与卵巢癌易感基因BRCA1和BRCA2

BRCA1和BRCA2是近年来发现的遗传性乳腺癌和卵巢癌易感基因,分别位于第17号和第13号染色体上。目前所知,两者与细胞周期调控、胚胎生 长发育、DNA损伤修复和转录调控等生命活动有关。随着BRCA1和BRCA2研究的不断深入和其确切生物学功能的阐明,将在临床上帮助早期诊断和有效治疗乳腺癌和卵巢癌患者。     

南京地区青年乳腺癌患者GSTM1、GSTT1 基因多态性与易感性 的初步研究

目的:研究GSTM1、GSTT1基因多态性与乳腺癌遗传易感性的关系。方法:应用PCR技术检测乳腺癌组和对照组人群GSTM1和GST T1基因。结果:GSTM 1和GSTT 1基因缺失率在乳腺癌组分别为63.4%(59/93)和54.8%(51/93),对照组分别为39.3%(35/89)和33.7%(30/89),两组比较,差异有统计学意义(P<0.01或P<0.05)。结论:GSTM1和GST T1缺失为乳腺癌遗传易感因素。     

乳腺癌易感基因研究进展

Ｂｒｃａｌ和Ｂｒｃａ２是乳腺癌易感基因,在家族性乳腺癌患者中的突变是可以遗传的,在散发性乳腺癌患者中有杂合性丢失（ＬＯＨ）,而且表达水平下降,体外实验证明,Ｂｒｃａｌ能抑制乳腺癌和卵巢癌细胞的的增殖。Ｂｒｃａｌ和Ｂｒｃａ２基因分别定位于１７ｑ１２－２１和１３ｑ１２－１３,编码序列５７１１ｂｐ和１０９８７ｂｐ,其表达有一定的组织特异性。ＢＲＣＡ１和ＢＲＣＡ２蛋白分别由１８６３个氨基酸和３４１８个氨基     

抑癌基因D L C-1 的研究进展

DLC-1（frequently deletedin liver cancer）基因是新发现的一个肿瘤抑制基因。它的失活有可能参与肿瘤的发生和发展。本文拟就DLC-1基因的结构功能及其在遗传和表遗传方面的失活机制作一综述。     

Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver

Deleted in liver cancer 1 (DLC-1), as its name implied, was originally isolated as a potential tumor suppressor gene often deleted in hepatocellular carcinoma. Further studies have indicated that down-expression of DLC-1 either by genomic deletion or DNA methylation is associated with a variety of cancer types including lung, breast, prostate, kidney, colon, uterus, ovary, and stomach. Re-expression of DLC-1 in cancer cells regulates the structure of actin cytoskeleton and focal adhesions and significantly inhibits cell growth, supporting its role as a tumor suppressor. This tumor suppressive function relies on DLC-1's RhoGTPase activating protein (RhoGAP) activity and steroidogenic acute regulatory (StAR)-related lipid transfer (START) domain, as well as its focal adhesion localization, which is recruited by the Src Homology 2 (SH2) domains of tensins in a phosphotyrosine-independent fashion. Therefore, the expression and subcellular localization of DLC-1 could be a useful molecular marker for cancer prognosis, whereas DLC-1 and its downstream signaling molecules might be therapeutic targets for the treatment of cancer.     

抑癌基因DLC-1在结肠癌细胞sw480中表达的研究

目的:初步探讨DLC-1基因在结肠癌细胞sw480中的表达改变及其可能机制;方法:采用RT-PCR和Western blot分析结肠癌细胞CaCo2、sw480的DLC-1表达情况;应用去甲基化药物5—氮杂胞苷处理DLC-1基因阴性表达的细胞株,观察用药前后该细胞DLC-1基因的表达水平、细胞周期、细胞增殖力和侵袭力的影响。结果:CaCo2细胞高表达DLC-1 mRNA,而sw480则呈现表达缺失。经去甲基化药物5—氮杂胞苷处理sw480后,DLC-1 mRNA恢复表达,比较用药前后sw480细胞增殖力下降、细胞周期被阻滞在G2期、细胞侵袭力减弱。结论:DLC-1基因可影响结肠癌细胞sw480的增殖能力和侵袭力,并使结肠癌细胞sw480细胞周期阻滞于G2期,DNA甲基化可能是导致DLC-1在sw480细胞中的失活的一个重要原因。     

Hepatitis B core protein promotes liver cancer metastasis through miR-382-5p/DLC-1 axis

The hepatitis B virus core protein (HBc), also named core antigen, is well-known for its key role in viral capsid formation and virus replication. Recently, studies showed that HBc has the potential to control cell biology activity by regulating host gene expression. Here, we utilized miRNA microarray to identify 24 upregulated miRNAs and 21 downregulated miRNAs in HBc-expressed HCC cells, which were involved in multiple biological processes, including cell motility. Consistently, the in vitro transwell assay and the in vivo tail-vein injection model showed HBc promotion on HCC metastasis. Further, the miRNA-target gene network analysis displayed that the deleted in liver cancer (DLC-1) gene, an important negative regulator for cell motility, was potentially targeted by several differentially expressed miRNAs in HBc-introduced cells. Introduction of miRNAs mimics or inhibitors and 3′UTR luciferase activity assay proved that miR-382-5p efficiently suppressed DLC-1 expression and its 3′-UTR luciferase reporter activity. Importantly, cotransfection of miR-382-5p mimics/inhibitors and the DLC-1 expression vector almost abrogated HBc promotion on cell motility, indicating that the miR-382-5p/DLC-1 axis is important for mediating HBc-enhanced HCC motility. Clinical HCC samples also showed a negative correlation between miR-382-5p and DLC-1 expression level. Furthermore, HBc-positive HCC tissues showed high miR-382-5p level and reduced DLC-1 expression. In conclusion, our findings revealed that HBc promoted HCC motility by regulating the miR-382-5p/DLC-1 axis, which might provide a novel target for clinical diagnosis and treatment.     

Deleted in breast cancer-1 (DBC-1) in the interface between metabolism,aging and cancer

DBC1 (deleted in breast cancer-1) is a nuclear protein that regulates cellular metabolism. Since alteration in cellular metabolism have been proposed to be the emerging ‘hallmark’ of cancer, it is possible that DBC1 may be implicated in the regulation of cancer cell energy metabolism. However, at this point any role of DBC1 in cancer is only speculative. In this review, we will discuss the new developments in DBC1 research, its molecular structure, regulatory roles and implication in metabolism, aging and cancer.